Zai Lab Ltd
ZLAB18.330USD
-0.250-1.35%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
2.03BMarket Cap
LossP/E TTM
More Details of Zai Lab Ltd Company
Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
Zai Lab Ltd Info
Ticker SymbolZLAB
Company nameZai Lab Ltd
IPO dateSep 28, 2020
CEODu (Ying)
Number of employees1869
Security typeDepository Receipt
Fiscal year-endSep 28
AddressBuilding B, 899 Halei Road, Pudong
CitySHANGHAI
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryChina
Postal code201203
Phone862161632588
Websitehttps://www.zailaboratory.com/
Ticker SymbolZLAB
IPO dateSep 28, 2020
CEODu (Ying)
Company Executives of Zai Lab Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. John David Diekman, Ph.D.
Dr. John David Diekman, Ph.D.
Lead Independent Director
Lead Independent Director
99.77K
+12.18%
Mr. Joshua L. Smiley
Mr. Joshua L. Smiley
President, Chief Operating Officer
President, Chief Operating Officer
86.60K
+13.05%
Mr. William David (Bill) Lis
Mr. William David (Bill) Lis
Independent Director
Independent Director
35.11K
-7.83%
Dr. Yajing Chen, Ph.D.
Dr. Yajing Chen, Ph.D.
Chief Financial Officer
Chief Financial Officer
17.44K
-1.36%
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Independent Director
Independent Director
--
--
Mr. Michel Pericles Vounatsos
Mr. Michel Pericles Vounatsos
Independent Director
Independent Director
--
--
Dr. Richard B. Gaynor, M.D.
Dr. Richard B. Gaynor, M.D.
Independent Director
Independent Director
--
--
Ms. Leung (Nisa Bernice) Wing-Yu
Ms. Leung (Nisa Bernice) Wing-Yu
Independent Director
Independent Director
--
--
Mr. Peter Karl Wirth, J.D.
Mr. Peter Karl Wirth, J.D.
Independent Director
Independent Director
--
--
Ms. Christine Chiou
Ms. Christine Chiou
Senior Vice President, Head - Investor Relations
Senior Vice President, Head - Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. John David Diekman, Ph.D.
Dr. John David Diekman, Ph.D.
Lead Independent Director
Lead Independent Director
99.77K
+12.18%
Mr. Joshua L. Smiley
Mr. Joshua L. Smiley
President, Chief Operating Officer
President, Chief Operating Officer
86.60K
+13.05%
Mr. William David (Bill) Lis
Mr. William David (Bill) Lis
Independent Director
Independent Director
35.11K
-7.83%
Dr. Yajing Chen, Ph.D.
Dr. Yajing Chen, Ph.D.
Chief Financial Officer
Chief Financial Officer
17.44K
-1.36%
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Independent Director
Independent Director
--
--
Mr. Michel Pericles Vounatsos
Mr. Michel Pericles Vounatsos
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
By BusinessUSD
Name
Revenue
Proportion
ZEJULA
41.04M
37.62%
VYVGART
26.50M
24.29%
NUZYRA
14.29M
13.10%
Optune
12.36M
11.33%
QINLOCK
8.54M
7.83%
Other
6.36M
5.83%
By RegionUSD
Name
Revenue
Proportion
China (Mainland)
109.98M
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
ZEJULA
41.04M
37.62%
VYVGART
26.50M
24.29%
NUZYRA
14.29M
13.10%
Optune
12.36M
11.33%
QINLOCK
8.54M
7.83%
Other
6.36M
5.83%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Capital World Investors
5.43%
Fidelity Management & Research Company LLC
3.82%
ClearBridge Investments, LLC
3.14%
RTW Investments L.P.
2.05%
Janus Henderson Investors
1.83%
Other
83.73%
Shareholders
Shareholders
Proportion
Capital World Investors
5.43%
Fidelity Management & Research Company LLC
3.82%
ClearBridge Investments, LLC
3.14%
RTW Investments L.P.
2.05%
Janus Henderson Investors
1.83%
Other
83.73%
Shareholder Types
Shareholders
Proportion
Investment Advisor
14.98%
Investment Advisor/Hedge Fund
12.61%
Hedge Fund
4.37%
Individual Investor
1.79%
Private Equity
1.45%
Venture Capital
1.13%
Research Firm
0.62%
Sovereign Wealth Fund
0.18%
Bank and Trust
0.05%
Other
62.84%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
372
46.61M
41.70%
-15.37M
2025Q2
394
60.58M
54.15%
-11.96M
2025Q1
453
59.51M
53.68%
-14.18M
2024Q4
446
60.80M
55.47%
-4.29M
2024Q3
439
51.45M
51.99%
-10.14M
2024Q2
454
47.04M
47.66%
-14.67M
2024Q1
465
46.22M
46.47%
-13.77M
2023Q4
497
46.31M
46.92%
-16.57M
2023Q3
537
44.27M
45.68%
-20.42M
2023Q2
568
47.21M
48.74%
-23.76M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Capital World Investors
6.04M
5.4%
+27.77K
+0.46%
Jun 30, 2025
Fidelity Management & Research Company LLC
4.89M
4.37%
+206.80K
+4.42%
Jun 30, 2025
ClearBridge Investments, LLC
4.01M
3.59%
+732.39K
+22.33%
Jun 30, 2025
RTW Investments L.P.
5.54M
4.95%
+2.40M
+76.52%
Jun 30, 2025
Janus Henderson Investors
2.20M
1.97%
-1.62M
-42.37%
Jun 30, 2025
Wellington Management Company, LLP
1.38M
1.23%
-2.27M
-62.25%
Jun 30, 2025
Frazier Life Sciences Management, L.P.
1.31M
1.17%
+958.14K
+273.75%
Jun 30, 2025
Segantii Capital Management Limited
1.56M
1.39%
-131.64K
-7.80%
Mar 31, 2024
Baron Capital Management, Inc.
1.59M
1.42%
-241.68K
-13.21%
Jun 30, 2025
Qiming Venture Partners
1.27M
1.13%
+1.27M
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Tema Oncology ETF
1.67%
ALPS Medical Breakthroughs ETF
1.19%
Virtus LifeSci Biotech Products ETF
0.97%
Invesco Golden Dragon China ETF
0.58%
National Security Emerging Markets Index ETF
0.39%
iShares Biotechnology ETF
0.18%
Capital Group New Geography Equity ETF
0.15%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.12%
ActivePassive International Equity ETF
0.03%
View more
Tema Oncology ETF
Proportion1.67%
ALPS Medical Breakthroughs ETF
Proportion1.19%
Virtus LifeSci Biotech Products ETF
Proportion0.97%
Invesco Golden Dragon China ETF
Proportion0.58%
National Security Emerging Markets Index ETF
Proportion0.39%
iShares Biotechnology ETF
Proportion0.18%
Capital Group New Geography Equity ETF
Proportion0.15%
ProShares Ultra Nasdaq Biotechnology
Proportion0.12%
Invesco Nasdaq Biotechnology ETF
Proportion0.12%
ActivePassive International Equity ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Zai Lab Ltd?
The top five shareholders of Zai Lab Ltd are:
Capital World Investors holds 6.04M shares, accounting for 5.40% of the total shares.
Fidelity Management & Research Company LLC holds 4.89M shares, accounting for 4.37% of the total shares.
ClearBridge Investments, LLC holds 4.01M shares, accounting for 3.59% of the total shares.
RTW Investments L.P. holds 5.54M shares, accounting for 4.95% of the total shares.
Janus Henderson Investors holds 2.20M shares, accounting for 1.97% of the total shares.
Capital World Investors holds 6.04M shares, accounting for 5.40% of the total shares.
Fidelity Management & Research Company LLC holds 4.89M shares, accounting for 4.37% of the total shares.
ClearBridge Investments, LLC holds 4.01M shares, accounting for 3.59% of the total shares.
RTW Investments L.P. holds 5.54M shares, accounting for 4.95% of the total shares.
Janus Henderson Investors holds 2.20M shares, accounting for 1.97% of the total shares.
What are the top three shareholder types of Zai Lab Ltd?
The top three shareholder types of Zai Lab Ltd are:
Capital World Investors
Fidelity Management & Research Company LLC
ClearBridge Investments, LLC
Capital World Investors
Fidelity Management & Research Company LLC
ClearBridge Investments, LLC
How many institutions hold shares of Zai Lab Ltd (ZLAB)?
As of 2025Q3, 372 institutions hold shares of Zai Lab Ltd, with a combined market value of approximately 46.61M, accounting for 41.70% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -12.45%.
What is the biggest source of revenue for Zai Lab Ltd?
In FY2025Q2, the ZEJULA business generated the highest revenue for Zai Lab Ltd, amounting to 41.04M and accounting for 37.62% of total revenue.
